Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Dendritic Cell Vaccine +/- CD40 Ligand in Stage III/IV Melanoma
NCT00053391Phase 2Completed
- Sponsor
- University Hospital Erlangen
- Start
- Oct 2002
- Primary completion
- Jun 2005
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Intus in melanoma, sponsored by University Hospital Erlangen. Started Oct 2002; status: completed.
02
Drugs
Intus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00053391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053391.